Recent News Releases

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and...

MADRID, Spain – 27 September 2019 – Global biotherapeutics leader CSL Behring will host a patient-focused symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 30 September, during the

The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative...

New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit. 23 Sep 2019 Seqirus, a global leader in influenza prevention, has...

This news release is intended for Health Professional media only. 17 Sep 2019 Seqirus, a global leader in influenza prevention, and Laboratoire Arrow, a fast growing player in the pharmaceutical...

St Gallen, 11 September 2019 – Vifor Pharma today announced changes to its management. Dr Klaus Henning Jensen will join the company as Chief Medical Officer and Member of the Executive...

St Gallen, 9 September 2019 – Vifor Pharma announced today that Standard & Poor's (S&P) assigned a BBBcredit rating with stable outlook to Vifor Pharma. This inaugural investment grade credit...

This news release is intended for Health Professional media only. Maidenhead, 5 September 2019 Seqirus, a global leader in influenza prevention, announced today that it has started on-time...

Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc....